Acumen Pharmaceuticals Inc Asset Resilience Ratio
Acumen Pharmaceuticals Inc asset resilience ratio. Acumen Pharmaceuticals Inc (ABOS) has an Asset Resilience Ratio of 57.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ABOS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Acumen Pharmaceuticals Inc (2020–2025)
Asset resilience ratio of Acumen Pharmaceuticals Inc from 2020 to 2025. This chart shows how Acumen Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Acumen Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Acumen Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Acumen Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $76.60 Million | 57.32% |
| Total Liquid Assets | $76.60 Million | 57.32% |
Asset Resilience Insights
- Very High Liquidity: Acumen Pharmaceuticals Inc maintains exceptional liquid asset reserves at 57.32% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Acumen Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Acumen Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Acumen Pharmaceuticals Inc Asset Resilience Ratio by Year (2020–2025)
Acumen Pharmaceuticals Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Acumen Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.19% | $62.88 Million | $122.83 Million | -5.69pp |
| 2024-12-31 | 56.88% | $135.93 Million | $238.99 Million | -0.08pp |
| 2023-12-31 | 56.96% | $176.64 Million | $310.12 Million | +32.79pp |
| 2022-12-31 | 24.16% | $47.50 Million | $196.59 Million | -7.13pp |
| 2021-12-31 | 31.29% | $72.08 Million | $230.33 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $44.43 Million | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement… Read more